If you are on the lookout for some big returns for your investment portfolio, then it could be worth checking out the two ASX 200 shares named below.
That's because they have just been tipped as buys with the potential to rise over 25% from current levels following sizeable share price declines this week.
Here's what these brokers are recommending to their clients:
Image source: Getty Images
CSL Ltd (ASX: CSL)
The team at E&P thinks that biotechnology giant CSL could be an ASX 200 share to buy following its sizeable pullback this week.
In response to its FY 2025 results, the broker has retained its positive (buy) rating on its shares with a trimmed price target of $294.21. Based on its current share price, this implies potential upside of 30% for investors over the next 12 months.
The broker believes that the selloff is a potential buying opportunity. Commenting on its recommendation, it said:
The key question is whether Behring's weak 2H25 signals structural pressure or a temporary setback. Management insists it's the latter, although medium-term Ig growth expectations have effectively eased to mid-to-high single digits (still respectable). At this stage, we retain our view the industry can adjust to manage over-supply risks (i.e. lower collections including 3P). On balance, we see the sell-off as a potential buying opportunity. Retain Positive rating.
James Hardie Industries plc (ASX: JHX)
This building products company could be another cheap ASX 200 share to buy right now. That's the view of analysts at Macquarie Group Ltd (ASX: MQG), which remain positive on the company despite its disappointing quarterly update.
The broker has put an outperform rating and $36.90 price target on its shares. Based on its current share price, this suggests that upside of 27% is possible between now and this time next year.
Macquarie thinks that investors should stick with James Hardie while it integrates the AZEK business and feels that balance sheet risks are manageable. It said:
Outperform. Market conditions are tough, but we think an evolving AZEK integration story, a slow bottoming of markets, and another material price correction are in support of a reassessment. Balance sheet risks are elevated, but covenant pressure still seems manageable.
Valuation: We lower our SOTP-based TP by 21% to $36.90, from $46.80, on earnings changes and an increase of NAM multiples by 2x on lower earnings. Our TP implies an EV/EBIT of 16.9x on recovering earnings versus a 10-yr average of 16x.
